Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature

Abstract

Background: Treatment of patients with severe liver dysfunction including hyperbilirubinemia secondary to liver metastases of gastrointestinal (GI) cancer is challenging. Regimen of oxaliplatin and fluoropyrimidine (FP)/folinic acid (FA) ± a monoclonal antibody (moAb), represents a feasible option considering the pharmacokinetics. Clinical data on the respective dosage and tolerability are limited and no recommendations are available. Methods: Consecutive patients with severe hyperbilirubinemia [>2 × upper limit of the normal range (ULN) and >2.4 mg/dl] due to liver metastases of GI cancer without options for drainage receiving oxaliplatin, FP/FA ± moAb were analyzed. To collect further data a review of the literature was performed. Results: A total of 12 patients were identified between 2011 and 2015. At treatment start, median bilirubin level was 6.1 mg/dl (>5 × ULN, range 2.7-13.6). The majority of patients (n = 11) received dose-reduced regimen with oxaliplatin (60-76%) and FP/FA (0-77%), rapidly escalating to full dose regimen. During treatment, bilirubin levels dropped more than 50% within 8 weeks or normalized within 12 weeks in 6 patients (responders). Median overall survival was 5.75 months (range 1.0-16.0 months) but was significantly prolonged in responders compared to nonresponders [9.7 and 3.0 months, p = 0.026 (two-sided test); 95% confidence interval (CI): 1.10-10.22]. In addition, case reports or series comprising a further 26 patients could be identified. Based on the obtained data a treatment algorithm was developed. Conclusion: Treatment with oxaliplatin, FP/FA ± moAb is feasible and may derive relevant benefits in patients with severe liver dysfunction caused by GI cancer liver metastases without further options of drainage.

Successful treatment with nivolumab in a patient with gastric cancer with severe liver failure resulting from multiple liver metastases: A case report

“…Quidde et al reported a literature review of 26 cases of secondary hyperbilirubinemia due to liver metastasis in patients with gastrointestinal cancer in 2016 ( 10 ). Among the 26 cases included, only one case of GC was documented, and the remaining 25 cases were of colorectal cancer.…”

Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

“…In addition, cytotoxic chemotherapy often requires dose reduction. This is a considerable concern, because intensive chemotherapy is required to achieve a sufficient response to alleviate hyperbilirubinemia[ 5 , 8 ]. Furthermore, the PS of patients with severe hyperbilirubinemia is often poor at the time of diagnosis and progressively worsens, making them more vulnerable to chemotherapy toxicity.…”

Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria

“…A “phase 1 study” conducted by The Organ Dysfunction Working Group of the National Cancer Institute demonstrated that oxaliplatin administrated at the standard dose of 130mg/m 2 was well tolerated for patients with all liver failure without alteration in the clearance of the platinum species from the plasma, but they did not report the rate of bilirubin in the severe liver dysfunction group ( 8 , 9 ). According to BC cancer agency, no adjustment dose is required for mild to moderate failure ( 10 , 11 ).…”